1350653-23-4

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-
• Synonyms: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-;5-fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine;5-fluoro-3-iodo-2H-pyrazolo[3,4-b]pyridine
• CAS NO: 1350653-23-4
• Molecular Formula: C₆H₃FIN₃
• Molecular Weight: 263.0109932
• Mol File: 1350653-23-4.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 382.7±37.0 °C(Predicted)
• Appearance: /
• Density: 2.294±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.86±0.40(Predicted)
• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-(1350653-23-4)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo-(1350653-23-4)

Safety Data

• Hazardous Substances Data: 1350653-23-4(Hazardous Substances Data)

Usage

General Description

The chemical 1H-Pyrazolo[3,4-b]pyridine, 5-fluoro-3-iodo- is a complex organic compound belonging to the heterocyclic chemical class. It contains several functional groups, including a pyrazolo[3,4-b]pyridine ring, an iodine atom and a fluorine atom. It is a heterocyclic compound, which means it contains atoms of at least two different elements as part of its rings. Due to its intricate structure, it is likely used in specialized chemical research and synthesis. As with many chemicals of this type, information about its properties such as melting and boiling points, density, and solubility might not be readily available as they depend on specific conditions and the compound's purity.

Upstream product

• 870063-52-8 2-chloro-3-hydroxymethyl-5-fluoropyridine 
• 38186-88-8 2-chloro-5-fluoronicotinic acid 
• 1034667-22-5 5-fluoro-1H-pyrazolo[3,4-b]pyridine-3-amine 
• 791644-48-9 2-chloro-5-fluoronicotinonitrile 
• 75302-64-6 2-chloro-5-fluoropyridine-3-carboxamide 
• 82671-02-1 2,6-dichloro-5-fluoro-pyridine-3-carbonitrile 
• 113237-20-0 2,6-dichloro-5-fluoropyridine-3-carboxamide 

Downstream Products

• 1350653-24-5 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 1350653-25-6 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-nitropyrimidine-4,6-diamine 
• 1350653-26-7 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile 
• 1350653-29-0 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazenyl]pyrimidine-4,6-diamine 
• 1350653-30-3 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine 
• 1350653-20-1 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yl}carbamate 
• 1350653-21-2 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate 
• 1350653-22-3 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate 
• 1383446-11-4 5-fluoro-3-(4,4,5,5-tetramethyl-1.3.2-dioxaborolan-2-yl)-1-trityl-1H-pyrazolo[3.4-b] pyridine 
• 1383446-18-1 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 
• 1383446-73-8 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 
• 1383447-77-5 C₄₀H₃₈F₂N₈O₂ 
• 1383446-78-3 N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)morpholine-4-carboxamide 
• 1383446-80-7 (R)-3-fluoro-N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)pyrrolidine-1-carboxamide 

Relevant articles and documents

Preparation method of 5-fluoro-3-iodo-1H-pyrazolo [3, 4-b] pyridine

The invention discloses a preparation method of 5-fluoro-3-iodo-1H-pyrazolo [3, 4-b] pyridine, and belongs to the field of medicinal chemistry. The method specifically comprises the following steps: S1, carrying out reduction reaction on 2-chloro-5-fluoronicotinic acid serving as a starting point to obtain 2-chloro-3-hydroxymethyl-5-fluoropyridine; S2,carrying out oxidation reaction on the 2-chloro-3-hydroxymethyl-5-fluoropyridineto obtain 2-chloro-3-formyl-5-fluoropyridine; S3, enabling that the 2-chloro-3-formyl-5-fluoropyridine is subjected to ring closing through hydrazine hydrate, so that 5-fluoro-1H-pyrazolo [3, 4-b] pyridine is obtained; and S4, carrying out an iodination reaction on the 5-fluoro-1H-pyrazolo [3, 4-b] pyridine, so as to obtain the 5-fluoro-3-iodo-1H-pyrazolo [3, 4-b] pyridine. The four-step reaction of the preparation method does not use strongly corrosive acidic materials, so that the preparation method has the advantages of high safety operability, small damage to equipment and facilities, high safety operability in material storage, transfer and use links, avoidance of diazonium salt reaction for releasing nitrogen in the prior art, high safety controllability, mild reaction conditions, higher safety, simplicity in operation, high yield, and suitability for industrial production.

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza

JNJ-63623872 (2) is a first-in-class, orally bioavailable compound that offers significant potential for the treatment of pandemic and seasonal influenza. Early lead optimization efforts in our 7-azaindole series focused on 1,3-diaminocyclohexyl amide and urea substitutions on the pyrimidine-7-azaindole motif. In this work, we explored two strategies to eliminate observed aldehyde oxidase (AO)-mediated metabolism at the 2-position of these 7-azaindole analogues. Substitution at the 2-position of the azaindole ring generated somewhat less potent analogues, but reduced AO-mediated metabolism. Incorporation of a ring nitrogen generated 7-azaindazole analogues that were equipotent to the parent 2-H-7-azaindole, but surprisingly, did not appear to improve AO-mediated metabolism. Overall, we identified multiple 2-substituted 7-azaindole analogues with enhanced AO stability and we present data for one such compound (12) that demonstrate a favorable oral pharmacokinetic profile in rodents. These analogues have the potential to be further developed as anti-influenza agents for the treatment of influenza.

PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.